00:17 , Feb 16, 2019 |  BioCentury  |  Finance

Andera looks early for cancer immunotherapy

Andera Partners changed gears with an early investment in preclinical company Grey Wolf Therapeutics to diversify its cancer immunotherapy portfolio. Along with Canaan Partners, Andera backed a £10 million ($12.9 million) series A for Grey...
18:23 , Feb 15, 2019 |  BC Week In Review  |  Financial News

Andera, Canaan lead Grey Wolf £10M A round

Cancer immunotherapy company Grey Wolf Therapeutics closed the second tranche of its total £10 million ($12.9 million) series A round to fund development of its immuno-oncology therapies to increase tumor visibility. The round was led...
06:05 , Feb 11, 2019 |  BC Extra  |  Financial News

Andera, Canaan lead Grey Wolf £10M A round

Cancer immunotherapy company Grey Wolf Therapeutics closed the second tranche of its total £10 million ($12.9 million) series A round to fund development of its immuno-oncology therapies to increase tumor visibility. The round was led...
08:00 , Jan 16, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Endoplasmic reticulum aminopeptidase 1 (ERAP1; ARTS1; ERAAP); ERAP2; insulin-regulated aminopeptidase (IRAP) In vitro and mouse studies identified inhibitors of ERAP1, ERAP2 and IRAP that...
08:00 , Dec 16, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Psoriasis TRAF3 interacting protein 2 (TRAF3IP2; ACT1); inducible nitric oxide synthase 2 (NOS2; iNOS); F-box and leucine-rich repeat protein 19...